SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Rudnick Stanford (Last) (First) (Middle) C/O SYNEOS HEALTH, INC. 1030 SYNC ST (Street) MORRISVILLE NC 27560 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 03/31/2023	3. Issuer Name and Ticker or Trading Symbol Syneos Health, Inc. [ SYNH ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) See remarks	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Class A Common Stock	31,518(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Class A Common Stock)	(2)	07/29/2025	Class A Common Stock	166	$43.16	D
Stock Option (Right to Buy Class A Common Stock)	(2)	01/19/2026	Class A Common Stock	537	$42.88	D

Explanation of Responses:

1. Includes (i) 408 restricted stock units ("RSUs") that vest on April 18, 2023; (ii) 612 RSUs that vest on April 18, 2023; (iii) 704 RSUs that vest on May 16, 2023; (iv) 704 RSUs that vest on January 15, 2024; (v) 2,345 RSUs that vest on January 17, 2024; (vi) 610 RSUs that vest on January 18, 2024; (vii) 1,407 RSUs that vest on February 15, 2024; (viii) 217 RSUs that vest on February 16, 2024; (ix) 408 RSUs that vest on April 18, 2024; (x) 612 RSUs that vest on April 18, 2024; (xi) 2,112 RSUs that vest on May 16, 2024; (xii) 5,782 RSUs that vest on December 15, 2024; (xiii) 2,345 RSUs that vest on January 17, 2025; (xiv) 611 RSUs that vest on January 18, 2025; (xv) 1,407 RSUs that vest on February 15, 2025; (xvi) 408 RSUs that vest on April 18, 2025; (xvii) 612 RSUs that vest on April 18, 2025; (xviii) 2,346 RSUs that vest on January 17, 2026; (xix) 1,408 RSUs that vest on February 15, 2026, all subject to continued employment.

2. The shares subject to this option are fully vested.

Remarks:

Interim Chief Financial Officer Exhibit List: Exhibit 24 - Power of Attorney

	/s/ Sara Epstein, Attorney-in-Fact	04/10/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.